An audit of immunohistochemical marker patterns in meningioma.
Meningiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routine in order to obtain data of individual expression of markers that may provide targets for anti-receptor treatment. One hundred and seventy-five consecutive patients operated on for meningiomas between 2005 and 2008 were prospectively analysed with antibodies against receptors for growth hormone, insulin-like growth factor 1 (IGF-1), androgen receptors, progesterone receptors (PR) and antibodies against CD34, VEGF, Ki-67 and caspase-3. Expression of IGF-1 receptor (IGF-1r), epidermal growth factor receptor (EGFR) E30 and growth hormone receptor (GHr) was conserved across histological grades and found in 88% to 94% of meningiomas. PR were detected in 87%, but expression decreased in aggressive tumours. Angio-markers such as VEGF and CD34 were detected in 69% and 17% of meningiomas, respectively. Androgen receptors and caspase-3 were uncommon. The analyses of a panel were undertaken as a clinical routine in order to assess its feasibility and to provide data that can be utilised in a clinical setting. Three putative therapeutic receptor targets, IGF-1r, GHr and EGFR E30 were expressed in a large majority of tumours and in contrast to PR maintained expression despite increasing pathological grade of meningioma. Our data also suggest that anti-progesterone therapies and anti-angiogenic therapies could be targeted to subsets of meningioma patients who express PR or have CD34-positive tumours.
Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden.
David S
DS
Baxter
Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
Abiel
A
Orrego
Department of Neurosurgery, Alfred Hospital, Monash University, Melbourne, VIC, Australia.
Jeffrey V
JV
Rosenfeld
Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden. Electronic address: tiit.mathiesen@karolinska.se.
Tiit
T
Mathiesen
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008579:Meningioma / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D055815:Young Adult
D014408:Biomarkers, Tumor
EGF; IGF; Meningioma; Neurosurgery; Progesterone; VEGF